Company intelligence / Profile preview

Immuneering Corporation

Ownership: Public · IMRX
Employees: ~66
Development stage: Preclinical

Overview

Immuneering's lead product candidate IMM-1-104 is in Phase 1/2a clinical trials for advanced solid tumors including pancreatic cancer. The FDA has granted Fast Track designation for IMM-1-104 for NRAS-mutant melanoma. Their second candidate IMM-6-415 is also in Phase 1/2a trials for advanced solid tumors with RAS or RAF mutations.

Therapeutic areas: Oncology
Modalities: Small moleculesOral therapeutics
Industry: Biotech

Drug pipeline

3 assets

atebimetinib

2 more assets in the full pipeline.

Request access →

Partnerships

Strategic collaborations with top-tier pharmaceutical companies

Financials

Market cap: $165.9M
Total revenue: $0
Enterprise value: $19.6M

Beyond the preview

Go deeper on Immuneering Corporation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immuneering Corporation.

Explore the full profile